Seeking Alpha

Washington University in St. Louis says it's selected Roche's (RHHBY.PK) gantenerumab and Eli...

Washington University in St. Louis says it's selected Roche's (RHHBY.PK) gantenerumab and Eli Lilly's (LLY -2.9%) solanezumab and beta secretase inhibitor for Alzheimer's prevention trials, expected to begin early 2013. The trials will be conducted  the university's Dominantly Inherited Alzheimer's Network Trials Unit, and is expected to involve 160 people with inherited gene mutations that typically lead to alzheimer's at young age.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|